Klaria Interim Report

Q2 2023  1 April - 30 June

Summary of the interim report

Net sales of 0.0 MSEK (3.7 MSEK)

Other income amounted to 0.3 MSEK (0.0 MSEK)

Second quarter of 2023

- R&D costs for the period amounted to 7.0 MSEK (14.7 MSEK)

- Profit after tax amounted to -10.1 MSEK (14.1 MSEK)

- Earnings per share for the quarter amounted to -0.09 SEK (-0.24 SEK)

- Cash flow from operating activities amounted to -2.2 MSEK (-15.7 MSEK)

- Cash and cash equivalents on the balance sheet date amounted to 8.9 MSEK (7.3 MSEK)

- Cash and cash equivalents on the balance sheet date amounted to 60.6 MSEK (57.7 MSEK)

The period January-June 2023

- Net sales of 6.5 MSEK (3.7 MSEK)

- Other income amounted to 0.3 MSEK (0.4 MSEK)

- R&D costs for the period amounted to 15.6 MSEK (31.8 MSEK)

- Profit after tax amounted to -15.5 MSEK (-34.8 MSEK)

- Earnings per share for the quarter amounted to -0.16 SEK (-0.61 SEK)

- Cash flow from operating activities amounted to -11.3 MSEK (-35.5 MSEK)

For more information, visit the  Klaria Pharma Holding website klaria.com or contact:
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.